Research article

Issn Print 2231 – 3648
Online 2231 – 3656

Available online at: www.ijpir.com

International Journal of Pharmacy and Industrial Research

RP-HPLC Method Development and Validation with Stability-Indicating Properties for a Multiple Sclerosis Drug

Shiva Kumar Tejavath[1], Perli. Kranti Kumar[*2], N. Sriram

[1]Assistant Professor, Department of Pharmaceutical Analysis, Sri Dattha Institute of Pharmacy, Hyderabad, Telangana.
[2*]Professor, Department of Pharmaceutical Analysis, Sri Indu Institute of Pharmacy, Hyderabad.
[3]Professor, Holy Mary Institute of Technology and Science, College of Pharmacy, Bogaram, Keesara, Hyderabad, India.

ABSTRACT

A basic and specific LC strategy is portrayed for the assurance of Dalfampridine tablet measurements structures. Chromatographic partition was accomplished on a c18 section utilizing portable stage comprising of a combination of Mixed Phosphate cradle (KH2PO4+K2HPO4) pH:3.5 Acetonitrile (30:70v/v/v), with discovery of 244 nm. Linearity was seen in the reach 35-105 µg/ml for Dalfampridine (r2 =0.998) for drugs assessed by the proposed strategies was in great concurrence with the name guarantee. A few scientific strategies have been proposed for the quantitative assessment of Dalfampridine independently and in blend with different medications. As far as anyone is concerned straightforward, quick insightful strategy for assurance of Dalfampridine has not been accounted for up until this point. So endeavor was taken to create and approve a switched stage superior execution fluid chromatographic technique for the quality control of Dalfampridine in drug arrangements with lower dissolvable utilization alongside the short logical run time that prompts a harmless to the ecosystem chromatographic system and will permit the examination of countless examples in a brief timeframe.

Keywords: Dalfampridine, RP-HPLC, Method development, Validation

INTRODUCTION

Dalfampridine is a neurofunctional modifier that further develops strolling speed in patients with different sclerosis. In MS, axons are continuously demyelinated which uncovered potassium channels. Subsequently, there is a hole of potassium particles which brings about the repolarization of cells and a lessening in neuronal excitability.[1] The general effect is the hindrance of neuromuscular transmission as setting off an activity potential is more enthusiastically. Dalfampridine represses voltage-gated potassium directs in the CNS to keep up with the transmembrane potential and draw out activity potential.[2] as such, Dalfampridine attempts to ensure that the current accessible is sufficiently high to animate conduction in demyelinated axons that are uncovered in MS patients. Besides, it works with neuromuscular and synaptic transmission by alleviating conduction blocks in demyelinated axons.[3] IUPAC name is 1-[2-(dimethylamino)-1-(4-methoxyphenyl) ethyl] cyclohexan-1-old. Sub-atomic equation C5H5N2. Sub-atomic Weight is 94.1.

Author for Correspondence:
Dr. Perli. Kranti Kumar, M. Pharm; Ph.D.
Email: drpkk1987@gmail.com
Professor, Department of Pharmaceutical Analysis, Sri Indu Institute of Pharmacy, Hyderabad.



Figure 1: Structure of Dalfampridine

The detailed solvency of Dalfampridine was tracked down in water, methanol, acetonitrile (ACN), CH3)2CO, ethyl ether, and exceptionally solvent in ethanol. It was seen as somewhat solvent in ligroin [4, 5]. The security of a medication in definition alludes to the capacity of a specific plan to keep up with its determinations connected with its personality, strength, quality, and immaculateness [6]. Corruption concentrates on over the medication can be determined by uncovering the medication in limits pH conditions (acidic or fundamental), oxidative responses, elated temperature, UV, and dry intensity to a degree of 5-20% [7, 8]. For examination of a medication and its substances, delicate techniques like LC/MS and GC/MS are liked yet are costly. The HPLC is viewed as the most solid and financially savvy [9, 10]. The techniques revealed by the utilization of opposite stage elite execution fluid chromatography (RP-HPLC) for the most part include the inclination method of examination, which makes investigation complex [11]. Thus, the ongoing work expects to foster an exact, explicit, solidness demonstrating, isocratic technique for the assessment of Dalfampridine in mass and tablet structure.

MATERIALS AND METHODS

Synthetic substances and Reagents

Dalfampridine Gift tests acquired from Madras drugs, Chennai. NaH2PO4 was logical grade provided by Finerchem restricted, Orthophosphoric corrosive (Merck), and Water and Methanol for HPLC (Lichrosolv (Merck).

Chromatographic Circumstances

The chromatography was performed on a Waters 2695 HPLC framework, furnished with an auto sampler, UV indicator and Engage 2 programming. Investigation was done at 244 nm with segment INERTSIL section, C18(150x4.6 ID) 5µm, aspects at Encompassing temperature. The upgraded portable stage comprises of Methanol: Acetonitrile: water (30:50:20 v/v/v). Stream rate was kept up with at 1 ml/min.

Arrangement of arrangements

Diluent Readiness

Portable stage is utilized as Diluent.

Standard

weigh precisely 10 mg of DALFAMPRIDINE in 100 ml of volumetric cup and disintegrate in 10ml of versatile stage and make up the volume with portable stage. From above stock arrangement 10 µg/ml of DALFAMPRIDINE is ready by weakening 1ml to 10ml with versatile stage. This arrangement is utilized for recording chromatogram.

Sample

5 TABLETS (each Tab contains 70 mg of DALFAMPRIDINE were gauged and taken into a mortar consistently blended. Test stock arrangements of DALFAMPRIDINE (100µg/ml) and was ready by dissolving weight identical to 100 mg of DALFAMPRIDINE and broken up in adequate portable stage. After that sifted the arrangement utilizing 0.45-micron needle channel and Sonicated for 5 min and weaken to 100ml with versatile stage. Further weakenings are ready in 5 reproduces of 10 µg/ml of DALFAMPRIDINE was made by adding 1 ml of stock answer for 10 ml of portable stage.

Procedure:20µL of the norm, test are infused into the chromatographic framework and the regions for tops are estimated and the %Assay are determined by utilizing the formulae.

METHOD

The created chromatographic strategy was approved for framework appropriateness, linearity exactness, accuracy, toughness and strength according to ICH rules.

System suitability parameters: To assess framework appropriateness boundaries, for example, maintenance time, following variable and USP hypothetical plate count, the versatile stage was permitted to course through the section at a stream pace of 1.0 ml/min for 30 minutes to equilibrate the segment at surrounding temperature. The overlay range of Dalfampridine was gotten and the Dalfampridine showed absorbance's maxima at 267 nm. Chromatographic detachment was accomplished by infusing a volume of 20 µL of standard into INERTSIL segment, C18(150x4.6 ID) 5µm section, the portable period of creation Methanol: Acetonitrile: water (30:50:20 v/v/v) was permitted to move through the segment at a stream pace of 1.0 ml each moment. Maintenance time, following variable and USP hypothetical plate count of the created technique are displayed in table 1.

Assay of pharmaceutical formulation: The proposed approved strategy was effectively applied to decide

Dalfampridine in tablet dose structure. The outcome got for was practically identical with the relating marked sums and they were displayed in Table-2.

Approval of Insightful strategy

Linearity: The linearity study was performed for the convergence of 35 µg/ml to 105 µg/ml level. Each level was infused into chromatographic framework. The region of each level was utilized for estimation of relationship coefficient. Infuse each level into the chromatographic framework and measure the pinnacle region. Plot a diagram of pinnacle region versus fixation (on X-pivot focus and on Y-hub Pinnacle region) and compute the relationship coefficient. The outcomes are displayed in table 3.

Precision studies: The not set in stone by help of recuperation study. The recuperation technique completed at three level 80%, 100%,120%. Infuse the standard arrangements into chromatographic framework. Work out the Sum found and Sum added for Dalfampridine and compute the singular recuperation and mean recuperation values. The outcomes are displayed in table 4.

Accuracy Studies: accuracy was determined from Coefficient of difference for six reproduce infusions of the norm. The standard arrangement was infused for multiple times and estimated the region for each of the six Infusions in HPLC. The %RSD for the area of six imitate infusions was found. The outcomes are displayed in table 5.

Ruggedness: To assess the middle accuracy of the technique, Accuracy was performed on various day. The standard arrangement was infused for multiple times and estimated the region for each of the six infusions in HPLC. The %RSD for the area of six recreate infusions was found. The outcomes are displayed in table 6.

Strength: As a feature of the Power, purposeful change in the Stream rate, Portable Stage piece was had to assess the effect on the strategy. The outcomes are displayed in table 7.

LOD and LOQ: The responsiveness of RP not entirely set in stone from LOD and LOQ. Which were determined from the alignment bend involving the accompanying conditions according to ICH rules. The outcomes are displayed in table 8.
LOD = 3.3σ/S and LOQ = 10 σ/S, where
σ= Standard deviation of y block of relapse line,
S = Incline of the alignment bend

Forced degradation studies

The constrained debasement study is viewed as a fundamental insightful part of the medication improvement program for little atoms. Constrained debasement, normally known as pressure testing, The ICH meaning of pressure testing for the medication item is "review embraced to survey the impact to serious circumstances on the medication item. Such investigations incorporate photograph strength testing and explicit testing on specific items like metered portion inhalers, creams, emulsions and so on. According to FDA rule "Solidness is characterized as the limit of a medication substance or medication item to stay inside laid out details to keep up with its personality, strength, quality, and immaculateness all through the retest or termination dating periods". The outcomes are displayed in table 9.

THERMAL DEGRADATION

Stress testing is probably going to be completed on single bunch of the medication substance (Programming interface). Thermolytic corruption might prompt hydrolysis/lack of hydration/isomerization/epimerization/decarboxylation/adjust ments and a few sorts of polymerization responses. ICH rules propose that thermolytic debasement study ought to be completed at temperatures (in 10 augmentations for example 50oC, 60oC, and so on) over that for sped up testing and pull out the example at various time stretches during response condition. On the off chance that sensible corruption (for example 5-20%) has seen, testing can be halted as of now.

PHOTOLYTIC DEGRADATION

The photochemical soundness of the medication was concentrated by uncovering the 100µg/ml answer for UV light by keeping the recepticle in UV chamber for 24 hours. For HPLC study, the resultant arrangement was infused into the framework and the chromatogram were recorded to evaluate the security of test.

ACIDIC DEGRADATION

Test arrangement (100µg/ml) ready and moved into a 50ml volumetric flagon and disintegrate in versatile stage up to 75% then sonicate it for 10 minutes then add 1 ml of 0.1N HCl then kept in broiler at 600c for 1 hour then cool and add 1 ml of 0.1N NaOH it then make up the volume up to 50ml with portable stage, then, at that point, place the example in the vial and measure the chromatogram.

BASE DEGRADATION

Test arrangement (100µg/ml) ready and moved into a 50ml volumetric flagon and disintegrate in portable stage up to 75% then sonicate it for 10 minutes then, at that point, add 1 ml of 0.1N NaOH then kept in broiler at 60°C for 1 hour then cool it and add 1 ml of 0.1N HCl then make up the volume up to 50ml with versatile. stage, then place the example in the vial and measure the chromatogram.

PEROXIDE DEGRADATION

Test arrangement of Ribociclib (100µg/ml) and 1 ml of 20% hydrogen peroxide (H2O2) was blended. For HPLC study, 100µg/ml were infused into the framework and the chromatogram was recorded to survey the solidness of test.

RESULTS AND DISCUSSION



Figure 2: Standard chromatogram



Figure 3: Sample chromatogram



Figure 4: Blank chromatogram

Table 1: System suitability parameters

Injection	Retention time (min)	Peak area
1	4.389	4256.908
2	4.387	4254.980
3	4.387	4250.876
4	4.387	4256.980
5	4.433	4256.083

6	4.438	4250.980
Mean	4.4035	4254.468
SD	0.0248	2.836
%RSD	**0.14**	**0.27**

Table 2: Assay results for Dalfampridine

DALFAMPRIDINE		
	Standard Area	**Sample Area**
Injection-1	4236.32	4260.493
Injection-2	4256.047	4236.32
Injection-3	4250.49	4256.047
Injection-4	4236.32	4262.647
Injection-5	4260.403	4252.55
Average Area	4247.916	4253.611
Tablet average weight		81
Standard weight		20
Sample weight		700
Label amount		70
std. purity		99.87
Amount found in mg		**2.03**
Assay(%purity)		**101.25**

Table 3: Linearity results of Dalfampridine

S. No.	Conc. (µg/ml)	Area
1	35	2490.485
2	52.5	3351.245
3	70	4207.305
4	87.5	5059.046
5	105	5933.427



Figure 5: Linearity graph for Dalfampridine

Table 4: Showing accuracy results for Dalfampridine

Recovery level	Accuracy				Average %	Recovery
	Amount taken(mcg/ml)	Area	Average area	Amount Recovered (mcg/ml)	%Recovery	
80%	70	**4266.47**	**4255.722**	**71.27**	**101.59**	100.45%
	70	**4240.819**				
	70	**4259.877**				
100%	87.5	**5166.633**	**5091.955**	**87.82**	**100.86**	
	87.5	**5054.273**				
	87.5	**5354.958**				
120%	105	**5833.427**	**5838.054**	**105.78**	**98.91**	
	105	**5822.224**				
	105	**5858.512**				

Table 5: Precision results for Dalfampridine

DALFAMPRIDINE		
S.No.	**Rt**	**Area**
1	4.38	4255.073
2	4.367	4184.798
3	4.437	4259.877
4	4.397	4262.854
5	4.437	4286.183
6	4.437	4259.877
avg	4.4092	4251.444
St dev	0.031934.450	
%RSD	**0.72**	**0.81**

Table 6: Ruggedness results of Dalfampridine

DALFAMPRIDINE	%Assay
Analyst 01	99.97
Analyst 02	100.11
%RSD	0.13

Table 7: Robustness results for Dalfampridine

Parameter	DALFAMPRIDINE	
	Retention time(min)	Tailing factor
Flow		
0.8ml/min	5.383	1.600
1.2ml/min	3.847	1.471
Wavelength		
331nm	4.463	1.487
335nm	4.450	1.526

Table 8: LOD, LOQ of Dalfampridine

Drug	LOD	LOQ
Dalfampridine	61.74	4.73

Table 9: Forced degradation study of Dalfampridine

Name of the Degradation	Condition	Peak Purity	k Purity Value	%Assay
Thermal Degradation	60°C/7Days	PASS	+	99.07
Photolytic Degradation	1.2mill/LUX Hours	PASS	+	99.01
Acid Degradation	HCl/4Hrs at 80°C	PASS	+	98.94
Base Degradation	5mL of 3N NaOH Solution/4Hrs at 80°C	PASS	+	98.97
Peroxide Degradation	5mL of 10% H_2O_2/4Hrs at Bench top	PASS	+	99.00

CONCLUSION

The Developed HPLC method was validated and it was found to be simple, precise, accurate and sensitive for the estimation of Dalfampridine in its pure form and in its pharmaceutical dosage forms. Hence, this method can easily and conveniently adopt for routine quality control analysis of Dalfampridine in pure and its pharmaceutical dosage forms.

REFERENCES

1. McDonald S, Clements JN (2011) Dalfampridine: a new agent for symptomatic management of multiple sclerosis. Am J Health Syst Pharm 68(24):2335–2340. https://doi.org/10.2146/ajhp110134
2. Tsang BK, Macdonell R (2011) Multiple sclerosis - diagnosis, management and prognosis. Reprints from Australian family physician. Focus Neurol 40(12):948–955
3. National Center for Biotechnology Information. PubChem database. 4- Aminopyridine, CID=1727. https://pubchem.ncbi.nlm.nih.gov/compound/4-a minopyridine. Accessed 1 Mar 2020
4. Madhumathi CH, Padmalatha M, Sneha D (2014) Development and validation of UV spectrometric method for the estimation of Dalfampridine in tablets. Int J Innov Pharm Sci Res 2(5):1019–1026
5. Redasan VK, Gazala LS, Surana SJ (2014) Development and validation of spectroscopic method for the estimation of Dalfampridine in bulk and in tablet formulation. Anal Chem Ind J 14(1):37–41
6. Raut, G; Shirkhedkar, A; Ugale, V; and Surana, S. (2014) Simultaneous determination of prednisolone acetate and moxifloxacin hydrochloride in bulk and in eye drop using RP– HPTLC. J Liquid Chromatogr Relat Technol 37:528–537.6. https://doi.org/10.1080/10826076.2012.749495, 4
7. Bendale AR, Narkhede SP, Palande S, Nagar AA, Vidyasagar GL (2013) Validated RP- HPLC method as a tool for estimation of lornoxicam in pharmaceutical dosage form. Indo Am J Pharm Res 3(7):5491–5498
8. Sethi PD, Sethi R (2007) High performance liquid chromatography, quantitative analysis of pharmaceutical formulation. CBS Publishers and Distributors, pp 2–7
9. Nagar A, Chugh N (2015) Simultaneous estimation method development as analytical method for flupentixol dihydrochloride and melitracen HCl from their combined pharmaceutical dosage forms by RP-HPLC. Pharm Innov J 4(1):81–86
10. EL-Fatatry HM, Hammad SF, Elagamy SH (2013) Validation of spectrofluorimetric determination of Dalfampridine in its synthetic mixture and spiked human plasma through derivatization with fluorescamine. J Anal Tech 3(1):23–26
11. Nagar A, Deore S, Bendale A, Kakade R, Sonawane C (2020) Analytical method development and validation of Ramipril and Candesartan Cillexetil in synthetic mixture. Innov Pharm Pharmacother 8(2):14–20. https://doi. org/10.31690/ipp.2020.v08i02.001
12. Kumar PK, Nilewar SS, Bonthu MG, Dudhe SP, Dudhe PB. Computational Drug Design and Docking Studies of Thiazole Derivatives Targeting Bacterial DNA Gyrase. Indian Journal of Pharmaceutical Chemistry and Analytical Techniques. 2025 Aug 7:40-53.
13. Bandaru N, Noor SM, Kammili ML, Bonthu MG, Gayatri AP, Kumar PK. Methionine restriction for cancer therapy: From preclinical studies to clinical trials. Cancer Pathogenesis and Therapy. 2025 Jan 6.
14. Bandaru N, Bonthu MG, Gayatri AP, Metri S, Kumar PK, Addanki A, Nallapaty S, Priya KS, Nadhreddy DT, Gowravi PN. Review on Exploring Role of Vitamin D on Alzheimer's Disease: Mechanistic Insights and Implications. Journal of Pharmacology and Pharmacotherapeutics. 2025 Jun;16(2):164-71.
15. Bandaru N, Noor SM, Kammili ML, Bonthu MG, Gayatri AP, Kumar PK. Cancer Pathogenesis and Therapy. International Journal of Pharmacy and Analytical Research (IJPAR).
16. Bharadwaj N, Das AB, Sunil R, Devi S, Kumar PK, Bhadkariya S, Kakkar S, IA C. asPotentialDPP-4InhibitorsforDiabetesManagement. Journal of Neonatal Surgery. 2025;14(12s):955.
17. Rekha NV, Kumar PK, Dasari V. Quantification And Phytochemical Examination Of Acacia Catechu Willd By HPTLC. Journal of Engineering Sciences. 2023;14(1):670-6.

18. Dudhe SP, Dudhe PB, Mundhe SM, Rojin RG, Vijukumar A, Cherian IV, Das S, Perli KK. The Digital Revolution in Education: Historical Perspectives and Future Directions. Revolutionizing Education With Remote Experimentation and Learning Analytics. 2025:489-508.
19. Behera A, Joshi V, Mohapatra R, Vishwakarma D, Sarkar S, Das S, Begum T, Kumar PK. Empagliflozin-Loaded Floating Density-Modulated Drug Delivery System as a Novel Approach for Sustained Therapy in Type 2 Diabetes Mellitus with Sodium-Glucose Co-Transporter-2 Inhibition. Cuestiones de Fisioterapia. 2025 Feb 19;54(3):4357-68.
20. Madhuri VD, Aparna TN, Dasari V, Kumar PK. A prospective of primary and novel approaches to the colon targeted drug delivery system.
21. Dhulipalla NL, Gadicherla V, Dasari V, Kumar PK. International Journal of Pharmacology and Clinical Research (IJPCR).
22. Uplanchiwar VP, Sarma KN, Mujawar T, Mythily V, Kranti P. Chronotherapeutic Circadian-Based Pulsatile Drug Delivery of Etodolac for Morning Stiffness in Rheumatoid Arthritis. Journal of Neonatal Surgery. 2025;14(4s):833.
23. Bandaru N, Shamim N, Nagalakshmi SB, Sunanda T, Hanisha C, Gambhire MS. Preparation of Platinum Nanoparticles of Biophytum reinwardtii and Evaluation of Neuroprotective Activity of MPTP-induced Parkinson's Disease in Zebra Fish. Biomedical and Pharmacology Journal. 2024 Sep 30;17(3):1635-45.
24. Krantikumar P, Godasu SK, Raju P, Vuyyala G, Dasari V. A study on method development and validation of drugs used in hospital acquired bacterial pneumonia. J Eng Sci. 2022;12:278-90.